Serial 97513593
Live / Registered — Registered (as of 16 Jul 2024)
What this means for you
Registered since 16 Jul 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97513593
- Registration number
- 7451384
- Mark type
- Design / logo
- Filed
- 21 Jul 2022
- Published for opposition
- 29 Aug 2023
- Registered
- 16 Jul 2024
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparation in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prosecution history
- 16 Jul 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 16 Jul 2024 — REGISTERED-PRINCIPAL REGISTER
- 16 Jul 2024 — REGISTERED-PRINCIPAL REGISTER
- 10 Jun 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 10 Jun 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 28 May 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 29 Apr 2024 — USE AMENDMENT FILED
- 26 May 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 29 Apr 2024 — TEAS STATEMENT OF USE RECEIVED
- 02 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Mar 2024 — SOU EXTENSION 1 GRANTED
- 30 Mar 2024 — SOU EXTENSION 1 FILED
- 30 Mar 2024 — SOU TEAS EXTENSION RECEIVED
- 24 Oct 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Aug 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED